Archivum immunologiae et therapiae experimentalis
-
We have investigated the effect of bestatin and thiorphan on growth of murine transplantable tumors, survival time, activity of natural killer (NK) cells and macrophages in mice. The injections of thiorphan at the does of 0.5 or 5 micrograms per mouse retarded tumor growth and prolonged survival period in B16 melanoma bearing animals. ⋯ The treatment with thiorphan at concentrations of 0.4-1.6 mg/ml inhibited growth of cultured in vitro B16 melanoma cell in comparison with control culture. Thiorphan added to the medium at concentration of 0.5 microgram/ml or administered 4 times at the dose of 0.5 microgram/mouse augmented NK lymphocyte activity.
-
Arch. Immunol. Ther. Exp. (Warsz.) · Jan 1995
Incidence of bone marrow transplantation in Europe. Report from the European Group for Blood and Marrow Transplantation.
The European Group of Blood and Marrow Transplantation (EBMT) is collecting information on incidence of bone marrow transplantation in Europe. 203 teams in 26 European countries performed in 1992 a total of 6065 bone marrow transplants (BMT). There were 2666 (44%) allogeneic transplants from 2171 HLA identical sibling donors, 170 non-identical family donors, 29 twin donors and 296 unrelated volunteer donors. ⋯ Transplant indications were leukemias in 2963 patients (49%) (1987 allogeneic, 976 autologous), lymphoproliferative disorders in 1890 patients (31%) (201 allogeneic, 1689 autologous), solid tumors in 739 patients (12%) (10 allogeneic, 739 autologous), aplastic anemia in 194 patients (3%) (193 allogeneic, 1 autologous), thalassemia in 128 patients (2%) (all allogeneic), inborn errors in 115 patients (2%) (all allogeneic) and miscellaneous disorders in 36 patients (32 allogeneic, 4 autologous). Main differences were observed in the number of transplanting teams, and in the number of allogeneic and autologous transplants performed in the different European countries compared to the number of inhabitants.